Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Melanoma 7Lung Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Pathologic Complete Response 2Pancreatic Neoplasms 2Neoplasm, Residual 2Hyperthermia 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Pneumonitis 1

Interventions

S 1 (combination) 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2zimberelimab 1surufatinib 1Radiosurgery 1Irinotecan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Pancreatic Cancer × Immunotherapy × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡